EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting

Florian Rosar, Fadi Khreish, Caroline Burgard, Artyom Fursov, Arne Blickle, Mark Bartholomä, Stephan Maus, Moritz B Bastian, Tilman Speicher, Andrea Schaefer-Schuler, Samer Ezziddin iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-04 · 53 (5) · 3034-3041

DOI: 10.1007/s00259-025-07682-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 28.11.2025. Verfasst von Florian Rosar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, Germany. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Dipeptides, Prostatic Neoplasms, Castration-Resistant, Lutetium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinDipeptidesProstatic Neoplasms, Castration-ResistantLutetiumHeterocyclic Compounds, 1-RingHumansMaleNitrilesAgedBenzamidesMiddle AgedAged, 80 and overTreatment OutcomeRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

EnzalutamidePSMAProstate cancerRLTRadioligand therapyRadiosensitizermCRPC

Substanzen

PhenylthiohydantoinenzalutamideNitrilesBenzamidesDipeptidesLutetiumHeterocyclic Compounds, 1-RingPSMA-617Lutetium-177Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, Germany.
  • Department of Nuclear Medicine, Marburg University - Campus Fulda, Fulda, Germany.
  • Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, Germany. samer.ezziddin@uks.eu.
  • Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany. samer.ezziddin@uks.eu.

ORCID-Profile: Samer Ezziddin

Zitieren

APA

Rosar, F., Khreish, F., Burgard, C., Fursov, A., Blickle, A., Bartholomä, M., Maus, S., Bastian, M. B., Speicher, T., Schaefer-Schuler, A., & Ezziddin, S. (2026). Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting. European Journal of Nuclear Medicine and Molecular Imaging, 53(5), 3034-3041. https://doi.org/10.1007/s00259-025-07682-5

Vancouver

Rosar F, Khreish F, Burgard C, Fursov A, Blickle A, Bartholomä M, et al. Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(5):3034-3041. doi:10.1007/s00259-025-07682-5

BibTeX
@article{Rosar2026,
  author = {Rosar, Florian and Khreish, Fadi and Burgard, Caroline and Fursov, Artyom and Blickle, Arne and Bartholomä, Mark and Maus, Stephan and Bastian, Moritz B and Speicher, Tilman and Schaefer-Schuler, Andrea and Ezziddin, Samer},
  title = {Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {5},
  pages = {3034--3041},
  doi = {10.1007/s00259-025-07682-5}
}
Kostenlos starten →